Document Detail


Effect of spironolactone on left ventricular ejection fraction and volumes in patients with class I or II heart failure.
MedLine Citation:
PMID:  21029826     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The beneficial effects of spironolactone in chronic heart failure (HF) have been demonstrated in patients with New York Heart Association (NYHA) class III to IV HF. This study examined the effect of spironolactone on left ventricular (LV) function and functional capacity of patients with mild to moderate HF (NYHA class I to II). One hundred sixty-eight patients with NYHA class I to II HF and LV ejection fraction ≤40% were randomized to spironolactone or placebo and assessed by echocardiography, gated single-photon emission computed tomography, technetium-99m sestamibi single-photon emission computed tomographic radionuclide ventriculography, and cardiopulmonary exercise testing at baseline and after 6 months of treatment. In the spironolactone group LV ejection fraction increased from 35.2 ± 0.7% to 39.1 ± 3.5% (p <0.001), with a decrease in LV end-diastolic and end-systolic volumes and myocardial mass and an improvement in LV diastolic filling pattern. Cardiopulmonary exercise testing parameters did not change. In conclusion, administration of spironolactone to patients with NYHA class I to II HF has beneficial effects on LV remodeling and diastolic function.
Authors:
Enrico Vizzardi; Antonio D'Aloia; Raffaele Giubbini; Tania Bordonali; Silvia Bugatti; Natalia Pezzali; Alessia Romeo; Alessandra Dei Cas; Marco Metra; Livio Dei Cas
Related Documents :
18617626 - Arterial-ventricular coupling: mechanistic insights into cardiovascular performance at ...
10871166 - The role of myocardial viability in deriving benefit from reestablishing infarct-relate...
19015406 - Direction of preoperative ventricular shunting affects ventricular mechanics after tetr...
18677436 - Clinical, angiographic and cardiovascular magnetic resonance findings in consecutive pa...
23079946 - Hierarchy and inhomogeneity in the systematic structure of the mammalian myocardium: to...
21438116 - Protease-activated receptors and myocardial infarction.
Publication Detail:
Type:  Journal Article; Randomized Controlled Trial     Date:  2010-09-09
Journal Detail:
Title:  The American journal of cardiology     Volume:  106     ISSN:  1879-1913     ISO Abbreviation:  Am. J. Cardiol.     Publication Date:  2010 Nov 
Date Detail:
Created Date:  2010-10-29     Completed Date:  2010-12-02     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0207277     Medline TA:  Am J Cardiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1292-6     Citation Subset:  AIM; IM    
Copyright Information:
Copyright © 2010 Elsevier Inc. All rights reserved.
Affiliation:
Department of Cardiology, University of Brescia, Italy. enrico.vizzardi@tin.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aldosterone Antagonists / therapeutic use*
Analysis of Variance
Biological Markers / blood
Echocardiography, Doppler
Exercise Test
Female
Heart Failure / drug therapy*,  physiopathology,  radionuclide imaging,  ultrasonography
Humans
Male
Middle Aged
Oxygen Consumption / physiology
Placebos
Radiopharmaceuticals / diagnostic use
Single-Blind Method
Spironolactone / therapeutic use*
Stroke Volume / drug effects*
Technetium Tc 99m Sestamibi / diagnostic use
Tomography, Emission-Computed, Single-Photon
Treatment Outcome
Chemical
Reg. No./Substance:
0/Aldosterone Antagonists; 0/Biological Markers; 0/Placebos; 0/Radiopharmaceuticals; 109581-73-9/Technetium Tc 99m Sestamibi; 52-01-7/Spironolactone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Meta-analysis of the effectiveness and safety of catheter ablation of atrial fibrillation in patient...
Next Document:  Effect of renal function on survival after implantable cardioverter defibrillator placement.